Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The overarching role of clinical trials is to measure the pros and cons of each drug to help us identify the best treatments for

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks. Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do. According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention habits, or disease treatments) work in people. Sometimes, a clinical trial is called a clinical

The National Comprehensive Cancer Network (NCCN) is an alliance of leading cancer centers across the United States working together to improve cancer care. NCCN develops evidence-based cancer care recommendations used by healthcare providers worldwide, and they release a companion version of the guidelines specifically for people with cancer and their caregivers. The newly updated and published guidelines for patients with small cell lung cancer can be viewed, downloaded, and printed here. Learn how treatment options have changed for patients with small cell lung cancer.

Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for free, or view the conference agenda. Last year’s conference was one of our most successful events yet, with over 900

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist presentations and discussions, this video focuses on patient-centric endpoints, showcases this collaboration from the

On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung cancer (SCLC). This targeted immunotherapy, the first of its kind, is based on new technology. Tarlatamab is a bispecific T-cell engager (BiTE)—a drug with two arms that simultaneously binds to a T cell (a part of the immune system) and a tumor cell. This allows the T cell to come close enough to the tumor cell to recognize and destroy it. Tarlatamab is a second-line treatment that can be considered if chemotherapy

Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of the Integrative Medicine Center at MD Anderson Cancer Center, explains how integrative medicine can be safely

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her expertise provides essential understanding for anyone interested in the complexities of lung cancer

This March, LUNGevity Foundation partnered with CURE for their ”Speaking Out” video series, featuring Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation. This interview with Dr. Moore delves into recent breakthroughs in the treatment of small cell lung cancer (SCLC). Dr. Moore discusses significant advances highlighted in clinical trials, such as the IMpower133 and CASPIAN studies, demonstrating the efficacy of combining immunotherapy with chemotherapy in improving survival rates for patients with extensive-stage SCLC. Visit our partners at

Join small cell lung cancer expert Lauren Byers, MD, as she covers the key things patients need to know about SCLC in 30 minutes. Dr. Byers is a professor in the Department of Thoracic-Head & Neck Medical Oncology at MD Anderson Cancer Center. She is also a physician-scientist and a member of LUNGevity’s Scientific Advisory Board. The following topics are discussed at the times indicated: 0:00 – 5:03 Introduction and explanation of what small cell lung cancer (SCLC) is 5:03 – 8:49 Key features and common symptoms 8:50 – 16:25 Understanding diagnosis and treatment 16:26 – 20:20 Discussion of